A Phase II Double-Blinded, Placebo-Controlled Trial of PROstate OligoMETastatic RadiotHErapy with or without ANdrogen Deprivation Therapy in Oligometastatic Prostate Cancer (NRG PROMETHEAN)

This study is being done to answer the following question:

Can we lower the chance of your prostate cancer growing or spreading by adding the drug
relugolix to the usual radiation therapy?

We are doing this study because we want to find out if this approach is better or worse than the
usual approach for your prostate cancer. The usual approach is defined as care most people
get for prostate cancer.